Results 11 to 20 of about 164 (107)

Lymphocyte dynamics in patients with multiple sclerosis who were treated with dimethyl fumarate and subsequently switched to diroximel fumarate

Brain Disorders
Objective: Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are oral multiple sclerosis (MS) disease-modifying therapies (DMTs). Absolute lymphocyte count (ALC) dynamics are similar for DMF and DRF, but have not been investigated in patients who ...
Shauna M. Gales, Ahmed Z. Obeidat, Andreina Neall, Kermit A. Lloyd, Nicholas Belviso, Seth Levin, Ivan Bozin, Jason P. Mendoza, James B. Lewin, Michael D. Kornberg   +9 more
doaj   +3 more sources

Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design

Biomedicines, 2023
Alzheimer’s Disease (AD) is a debilitating disease that leads to severe cognitive impairment and functional decline. The role of tau hyperphosphorylation and amyloid plaque deposition in the pathophysiology of AD has been well described; however ...
Robert Sharkus, Richa Thakkar, Dennis L. Kolson, Cris S. Constantinescu   +3 more
doaj   +2 more sources

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Neurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay   +7 more
doaj   +3 more sources

Diroximel fumarate to treat multiple sclerosis

Drugs of Today, 2020
On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl fumarate (DMF), was approved for the same indication on March 27, 2013.
Y, Wang, P, Bhargava
openaire   +3 more sources

Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study

Clinical Drug Investigation
Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world ...
Aguirre, Clara, Alonso-Torres, Ana, Agüera, Eduardo, García-Domínguez, José Manuel, Montero-Escribano, Paloma, González-Quintanilla, Vicente, Costa-Frossard, Lucienne, Oreja-Guevara, Celia, Reyes-Garrido, Virginia, Caminero-Rodríguez, Ana Belén, Riancho, Javier, Sánchez, Octavio, Forero, Lucía, Pérez-Parra, Fernando, Ares-Luque, Adrián, Téllez, Nieves, Arzalluz-Luque, Joaquín, Iglesias, Federico, Casado-Ruiz, Virginia, Castellano-Vicente, Alberto José, Borrega, Laura, Galán, Victoria, de Antonio, Luis A Rodríguez, Romero, Carlos, García-Rodríguez, Raquel, Cano-Orgaz, Antonio Tomás, Sánchez-Menoyo, José Luis, Pérez-Ruiz, Domingo, Gutiérrez-Martin, Fuencisla, Hernández-Echevarría, Luis, Meca-Lallana, Virginia   +30 more
openaire   +10 more sources

Crystal Structures of Large-Volume Commercial Pharmaceuticals [PDF]

Structural Dynamics
As part of a continuing project, the room-temperature crystal structures of 17 commercial pharmaceutical APIs have been solved and refined using synchrotron X-ray powder diffraction data (11-BM at APS and Wiggler Low Energy Beamline at CLS), and ...
James A Kaduk, Anja Dosen, Thomas N Blanton   +2 more
doaj   +2 more sources

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Neurology and Therapy
Introduction In EVOLVE-MS-1 (NCT02634307), mean absolute lymphocyte count (ALC) on diroximel fumarate (DRF) declined from baseline by approximately 28% in year 1, then stabilized, similar to ALC decline observed with dimethyl fumarate (DMF).
Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar   +12 more
doaj   +2 more sources

Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry [PDF]

Therapeutic Advances in Neurological Disorders
Background: The spectrum of disease-modifying therapies (DMTs) for people with multiple sclerosis (PwMS) has expanded over years, but data on treatment strategies is largely lacking. DMT switches are common clinical practice.
Niklas Frahm, David Ellenberger, Alexander Stahmann, Firas Fneish, Daniel Lüftenegger, Hans C. Salmen, Ksenija Schirduan, Tom P. A. Schaak, Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, Melanie Peters, Clemens Warnke   +14 more
doaj   +3 more sources

18 kDa Translocator protein (TSPO) is upregulated in rat brain after peripheral nerve injury and downregulated by diroximel fumarate

Brain, Behavior, and Immunity
Neuroimmune signaling is a key process underlying neuropathic pain. Clinical studies have demonstrated that 18 kDa translocator protein (TSPO), a putative marker of neuroinflammation, is upregulated in discrete brain regions of patients with chronic pain.
Cazuza, Rafael A., Zagrai, Sever M., Grieco, Anamaria R., Avery, Thomas D., Abell, Andrew D., Wey, Hsiao-Ying, Loggia, Marco L., Grace, Peter M.   +7 more
openaire   +3 more sources

Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons

Diabetes
Diabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes pain hypersensitivity in mice by stimulating the phosphorylation of eukaryotic initiation factor 2α (p-eIF2α) and subsequently activating the integrated stress response (ISR).
Yousuf, Muhammad Saad, Mancilla Moreno, Marisol, Woodall, Brodie J., Thakur, Vikram, Li, Jiahe, He, Lucy, Arjarapu, Rohita, Royer, Danielle, Zhang, Jennifer, Chattopadhyay, Munmun, Grace, Peter M., Price, Theodore J.   +11 more
openaire   +3 more sources